Mark Hogarth
Burnet Principal for Research Strategy; Head, Infl
Life Sciences
Burnet Institute
Australia
Biography
Professor Hogarth has had significant experience in translational research and technology transfer as an inventor and researcher with licenses of his laboratory’s intellectual property to national and international companies. His corporate roles have included Directing the Austin Research Institute and more recently as Director of Commercialisation and Research Strategy at the Burnet Institute.
Research Interest
Professor Hogarth is researching the role of immune system in intractable human diseases, particularly in autoimmunity cancer and inflammation. The research investigates the fundamental roles of immune cells, their receptors and their antibodies, and how these can be manipulated for the treatment of human disease. The research program involves basic, applied and translational projects that have led to fundamental discoveries of immune function and to the subsequent development of potential biological and drug therapeutics for the treatment of inflammation, cancer or infection.
Publications
-
HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV. Madhavi V, Wines BD, Amin J, Emery S; ENCORE1 study group, Lopez E, Kelleher A; Sydney LTNP study group, Center RJ, Hogarth PM, Chung AW, Kent SJ, Stratov I J Virol. 2017 Aug; 91(18):e00700-17
-
Antibody-dependent cellular cytotoxicity (ADCC) responses to seasonal influenza vaccination in older adults. Vanderven HA, Jegaskanda S, Wines BD, Hogarth PM, Carmuglia S, Rockman S, Chung AW, Kent SJ J Infect Dis. 2017 Nov; Epub ahead of print
-
Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults. Ana-Sosa-Batiz F, Johnston APR, Hogarth PM, Wines BD, Barr I, Wheatley AK, Kent SJ Vaccine. 2017 Nov; 35(47):6451-6458
